๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)

RecruitingNAAges 18 Years - 42 YearsFemaleMแปน ฤแปฉc Hospital
NCT06372119 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this randomized clinical trial is to evaluate the effectiveness of the letrozole-stimulated cycle strategy versus the artificial cycle strategy for endometrial preparation in women with irregular menstrual cycles after one cycle of endometrial preparation. The primary question it aims to answer is: โ€ข Does the letrozole-stimulated cycle strategy for endometrial preparation result in a higher live birth rate compared to the artificial cycle strategy in women with irregular menstrual cycles after one cycle of endometrial preparation? Participants will undergo screening before endometrial preparation for frozen embryo transfer, following which they will be randomly assigned to one of two groups: LETS or AC. In the LETS group, investigators will prescribe letrozole 5 milligrams/day for 5 days to stimulate follicular development and micronized progesterone 800 milligrams/day for

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Aged between 18 - 42. * Irregular menstrual cycle (\< 21 days or \> 35 days or \< 8 cycles/years). * Indicated for endometrial preparation. * Transfer of only one blastocyst. * Not participating in any other trials. Exclusion Criteria: * Allergy to letrozole or Ovitrelle or oral estradiol valerate or micronized progesterone * Having embryos from either oocyte donation or PGT (pre-implantation genetics testings) cycles. * Ovarian cysts that are unrelated to the oocyte pick-up. * Confirmed diagnosis with recurrent pregnancy loss (RPL) according to ESHRE guideline 2023, recurrent implantation failure (RIF) according to ESHRE 2023 good practice recommendations. * Endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, and chronic endometritis. * Uterine abnormalities include leiomyomas L0, L1, or L2 (according to FIGO 2011); adenomyosis (according to MUSA 2022); congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate (according to ASRM 2021). * Untreated hydrosalpinx.
๐Ÿ’Š

What it tests

  • Letrozole-stimulated cycle strategy
  • Artificial cycle strategy
๐Ÿ“

Where

2 sites
My Duc Hospital
Ho Chi Minh City, Vietnam
My Duc Phu Nhuan Hospital
Ho Chi Minh City, Vietnam
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy